Skip to main content
Figure 4 | Molecular Cancer

Figure 4

From: CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis

Figure 4

The MAPK/ ERK/ SRC pathway underlies CD133 expression. (A) No alteration of the protein expression levels of pERK and pSRC was detected inCapan1M9, shCD133M9 or shSlugM9 cells. (B) CD133 and Slug expression decreased after ERK1/2 inhibitor (10 μg/mL) treatment; results were validated by real-time RT-PCR. (C) CD133 protein expression decreased drastically after ERK1/2 inhibitor (10 μg/mL) treatment, as shown by Western blot analysis. (D) CD133 protein expression decreased dynamically after SRC inhibitor (10 μg/mL) treatment, as shown by Western blot analysis.

Back to article page

Molecular Cancer

ISSN: 1476-4598